Andecaliximab

Andecaliximab is a recombinant chimeric IgG4 monoclonal antibody (mAb) targets matrix metalloproteinase 9 (MMP9) . Andecaliximab shows the antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. Andecaliximab can be used for the research of gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF) [1][2].

Product Specifications

CAS Number

[1518996-49-0]

Product Name Alternative

Anti-MMP9 Reference Antibody (andecaliximab)

UNSPSC

12352203

Target

MMP

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/andecaliximab.html

Purity

99.0

Solubility

10 mM in DMSO

Smiles

[Andecaliximab]

Molecular Weight

(150 kDa)

References & Citations

[1]Andrew E. Greenstein, et al. Effect of andecaliximab (anti-MMP9) on proteolysis of IL-7 in vitro, TCR diversity in mice, and serum IL-7 in gastric cancer patients in combination with chemotherapy. 2018 ASCO-SITC Clinical Immuno-Oncology Symposium.|[2]Espindola MS, et al. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021 Feb 15;203 (4) :458-470.